LabCorp COVID-19 molecular test innovation receives FDA authorization

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 2, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that it is the first commercial laboratory to receive an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new, high-throughput method that uses heat and technology to extract RNA from samples collected for COVID-19 molecular testing. The advancement will help the company improve the speed and efficiency of RT-PCR tests, considered the ‘gold standard’ for active infections.1

19 Organizations from the healthcare community unite to form COVID-19 testing industry consortium

Consortium members will work together to increase opportunities to accelerate research through enhanced collaboration and information sharing, with the ultimate goal of improving aspects of COVID-19 testing across the globe.

LabCorp and Infirmary Health form strategic partnership to provide Laboratory services across healthcare system

Multi-year deal will enhance lab services for patients and providers throughout eastern Gulf Coast region.

LabCorp to announce third quarter financial results on October 27, 2020

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 28, 2020-- LabCorp (NYSE: LH) will release its third quarter of 2020 financial results before the market opens on Tuesday, Oct. 27, 2020 , and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

LabCorp and GENFIT sign exclusive agreement to commercialize a novel diagnostic test for liver disease

LILLE, FRANCE; CAMBRIDGE, MA; & BURLINGTON, N.C.—Sep. 28, 2020— GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, and LabCorp® (NYSE:LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, have agreed to a five-year exclusive licensing agreement for GENFIT’s NIS4™ technology to help identify patients with at-risk non-alcoholic steatohepatitis (NASH).

New non-invasive test for lung cancer available exclusively from Labcorp

Blood-based test guides treatment decisions for patients with non-small cell lung cancer